我要投票 隆顺榕在中草药行业中的票数:512
· 外 推 电 报 ·
2025-09-22 09:35:23 星期一

【隆顺榕是哪个国家的品牌?】

隆顺榕是什么牌子?「隆顺榕」是 天津中新药业集团股份有限公司 旗下著名品牌。该品牌发源于天津,由创始人李立群在1981-12-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力隆顺榕品牌出海!将品牌入驻外推网,定制隆顺榕品牌推广信息,可以显著提高隆顺榕产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

中新药业天津隆顺榕制药厂前身是创办于1833年的天津隆顺榕药局,至今己有170余年的发展历史。隆顺榕药局因其品佳质优,经营有术,声誉卓著而成"卫"药魁首。1957年隆顺榕与乐仁堂提炼部合并组建成中药提取制剂的专业生产厂家,即中新药业天津隆顺榕制药厂。中新药业天津隆顺榕制药厂在继承优良传统的基础上,不断创新,其产品以"选材地道、配制精良、工艺先进、疗效确切、功效卓著"而深孚众望、驰名中外,远销港、澳、台、新马等地,曾经是天津市中成药出口基地,全国21家重点中成药生产企业之一。

中新药业天津隆顺榕制药厂多年来一直致力于中药剂型改革的探索和中药技术的研究,是中国中药现代化的发源地。在科研开发、质量管理、生产经营、人才引用等方面都开创了中药制药史的先河:它于1952年在全国首家成立中成药研究机构及全国第一个中药提炼部,并引进了中药界有史以来的第一位留洋博士将传统的中医药理论与现代制剂技术相结合进行中药剂型改革的研究,研制出了第一个中成药片剂-银翘解毒片;第一个中成药酊剂-藿香正气水;第一个中药颗粒剂-当归四逆汤;第一个中药针剂-穿心莲等多种中药新剂型。

在软件建设方面:中新药业天津隆顺榕制药厂是天津首家在生产质量管理中推行全品种标准作业书规范化生产的中成药生产企业,形成了中国中药制药企业的GMP最早的软件雏型。

目前中新药业天津隆顺榕制药厂拥有液剂、片剂、颗粒剂三条生产线,88个注册品种。许多品种曾多次获奖,其中精制银翘解毒片自1958年就开始出口14个国家及地区,一直延续至今,多次荣获天津市优质产品称号;藿香正气水1979年荣获国家银质奖,在以后历届全国同类品种评比中都获得第一。小儿金丹片荣获1983年、1990年《中国妇女儿童用品四十年》博览会金奖。近年来又开发研制出了一系列新品:治疗糖尿病的纯中药制剂金芪降糖片,治疗泌尿系统感染的医院急诊必备中成药癃清片,达到美国FDA新药研究水平的中药复方抗癌药紫龙金片。

中新药业天津隆顺榕制药厂在新的发展形势下确立了"做中药精品创国粹名牌"的企业生存理念,在诚信的基础上推崇以"创新"为核心的企业文化。在销售工作中倡导"诚信经营"的理念;在生产工作中倡导"质量至上"的理念;在技术工作中倡导"创新发展"的理念;在人力资源管理工作中倡导"以人为本"的理念。在过去的三年中,企业已初步成为天津市同行业的排头企业。

企业在发展规划中提出:倡导以“创新”为核心的企业文化,追求卓越,实现企业价值最大化;提供优质产品和服务,为人类创造健康,为社会创造财富;对员工负责满足员工生活和成长需要,使其物质利益和精神利益得以实现;投身社会公益事业,做富有爱心的企业,体现企业的社会价值;传承卫药文化,打造“隆顺榕”强势品牌的指导思想和建立以市场为导向的内部管理机制,重点培养紫龙金片、金芪降糖片的技术含量,为紫龙金片冲击中药抗癌药前三甲,金芪降糖片冲击中药降糖药第一品牌奠定基础;确保员工平均收入年增长幅度不低于8%,人均年累计培训时间不低于96课时;建立合理的人才结构,为企业发展提供人力资本保证;实施差异化发展策略,打造“人无我有,人有我优”的企业核心竞争力;力争将隆顺榕打造成为中国中药行业驰名企业的总体发展目标。

企业决策层认为:曾经引领中国中药工业革命、一度代表天津乃至全国中药工业水平、在中国制药史上留下那么多可圈可点篇章的隆顺榕正面临再次腾飞的历史机遇。拥有紫龙金、金芪降糖片等优秀产品,拥有众多想干事、能干事的员工,背靠着各级领导对企业巨大的政策支持,依托着一百多年来的文化积淀,蕴藏着企业不断创新的动力源泉。不断在继承的基础上进步和发展,这正是隆顺榕的优势所在。

传承百年的隆顺榕,基奠隆顺榕的未来,是历史赋予每个隆顺榕人的重要使命。要站在振兴国粹、推动隆顺榕走向世界的高度上,站在济世寿人、泽及四方、靠企业优秀品质赢取天下人心的境界上,把握明天、决胜今天!未来的隆顺榕一定会更加壮丽!

英文翻译:China new pharmaceutical Tianjin longshunrong pharmaceutical factory was founded in 1833 by Tianjin longshunrong pharmaceutical Bureau. It has a history of 170 years. Longshunrong pharmaceutical Bureau has become the leader of "Wei" medicine for its excellent quality, skillful operation and outstanding reputation. In 1957, longshunrong and lerentang refining department were combined to form a professional manufacturer of Chinese medicine extraction preparations, namely Tianjin longshunrong pharmaceutical factory of China new pharmaceutical industry. Tianjin longshunrong pharmaceutical factory of China New Pharmaceutical Co., Ltd. keeps innovating on the basis of inheriting the fine tradition. Its products are well-known at home and abroad with "authentic material selection, excellent preparation, advanced technology, exact curative effect and outstanding effect". They are exported to Hong Kong, Macao, Taiwan, Xinma and other places. They used to be the export base of Tianjin Chinese patent medicine and one of the 21 key Chinese patent medicine manufacturers in China. Tianjin longshunrong pharmaceutical factory of China New Pharmaceutical Co., Ltd. has been committed to the exploration of traditional Chinese medicine dosage form reform and the research of traditional Chinese medicine technology for many years, which is the birthplace of the modernization of traditional Chinese medicine in China. In scientific research and development, quality management, production and operation, talent introduction and other aspects, it has pioneered the history of traditional Chinese medicine: it was the first to establish a Research Institute of Chinese patent medicine and the first Chinese medicine refining department in 1952 in China, and introduced the first overseas Chinese scholar in the history of traditional Chinese medicine to combine traditional Chinese medicine theory with modern preparation technology for the research of Chinese medicine dosage form reform, The first Chinese medicine tablet Yinqiao Jiedu tablet, the first Chinese medicine tincture Huoxiang Zhengqi water, the first Chinese medicine granule Danggui Sini Decoction, the first Chinese medicine injection Andrographis paniculata and other new Chinese medicine dosage forms have been developed. In terms of software construction: Tianjin longshunrong Pharmaceutical Co., Ltd. of China new pharmaceutical industry is the first Chinese patent medicine manufacturer in Tianjin to carry out standardized production of full variety standard operation manual in production quality management, forming the earliest software prototype of GMP for Chinese traditional medicine pharmaceutical enterprises. At present, China new pharmaceutical Tianjin longshunrong pharmaceutical factory has three production lines of liquid, tablet and granule, with 88 registered varieties. Many varieties have won many awards, among which refined Yinqiao antidote tablets have been exported to 14 countries and regions since 1958, and have been awarded the title of high-quality products in Tianjin for many times. Huoxiang Zhengqi water won the National Silver Award in 1979, and won the first prize in successive national similar varieties evaluation. Children's golden pill won the gold medal of China Women's and children's articles 40 years exposition in 1983 and 1990. In recent years, a series of new products have been developed: Jinqi Jiangtang Tablet, a pure Chinese medicine preparation for diabetes, Huangqing tablet, a necessary Chinese patent medicine for emergency treatment of urinary tract infection, and Zilongjin tablet, a Chinese medicine compound anticancer drug, which has reached the level of new drug research of FDA in the United States. Under the new development situation, Tianjin longshunrong Pharmaceutical Co., Ltd. of China New Pharmaceutical Co., Ltd. has established the enterprise survival concept of "making excellent traditional Chinese medicine and creating national quintessence and famous brand", and on the basis of honesty, it advocates the enterprise culture with "innovation" as the core. It advocates the concept of "honest management" in the sales work, the concept of "quality first" in the production work, the concept of "innovative development" in the technical work, and the concept of "people-oriented" in the human resource management work. In the past three years, the enterprise has initially become the leading enterprise in the same industry in Tianjin. In the development plan, the enterprise proposes: advocating the corporate culture with "innovation" as the core, pursuing excellence and maximizing the value of the enterprise; providing high-quality products and services, creating health for human beings and wealth for the society; being responsible for the employees to meet their life and growth needs, and realizing their material and spiritual interests; participating in social public welfare undertakings and being caring The enterprise embodies the social value of the enterprise; inherits the health medicine culture, creates the guiding ideology of "longshunrong" strong brand and establishes the market-oriented internal management mechanism, focuses on training the technical content of Zilongjin tablet and jinqijiangtang tablet, lays the foundation for Zilongjin tablet to impact the top three anti-cancer drugs of traditional Chinese Medicine, jinqijiangtang tablet to impact the first brand of traditional Chinese medicine; ensures the average staff The annual growth rate of income shall not be less than 8% and the annual accumulated training time per capita shall not be less than 96 class hours; a reasonable talent structure shall be established to provide human capital guarantee for the development of the enterprise; the differentiated development strategy shall be implemented to create the core competitiveness of the enterprise of "no one has me, and no one has me". The overall development goal of building longshunrong into a well-known enterprise in Chinese traditional medicine industry shall be strived for. The enterprise decision-makers believe that long Shunrong, who once led the revolution of Chinese traditional medicine industry, once represented Tianjin and even the level of Chinese traditional medicine industry, and left so many remarkable chapters in the history of Chinese pharmaceutical industry, is facing a historical opportunity to take off again. It has excellent products such as Zilongjin, Jinqi Jiangtang Tablet, and many employees who want to and can do things. It relies on the huge policy support of leaders at all levels for the enterprise, relies on the cultural accumulation of more than 100 years, and contains the power source of continuous innovation of the enterprise. Continuous progress and development on the basis of inheritance are the advantages of longshunrong. It is an important mission given by history to each person of longshunrong to inherit and lay the foundation for the future of longshunrong. We should stand on the height of revitalizing the quintessence of our country, promoting longshunrong to go to the world, on the realm of helping Shishou people, Ze and Sifang, and winning the hearts of the world by relying on the excellent quality of enterprises, and grasp tomorrow and win today! Longshunrong will be more magnificent in the future!

本文链接: https://www.waitui.com/brand/6a6702562.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

消息称萨克斯全球谈判出售Bergdorf Goodman近半股份

据知情人士称, 美国奢侈品连锁百货公司萨克斯全球(Saks Global)正就出售奢侈品零售商Bergdorf Goodman的49%股份进行谈判,价格约为10亿美元。消息人士称,至少有四家竞标者参与竞购,包括中东主权财富基金和战略投资者,交易可能于明年初达成。(新浪财经)

2小时前

8月份民航运输规模再创历史新高

近日,从民航局获悉,今年8月份,我国民航运输规模再创历史新高,运输总周转量首次突破150亿吨公里,整体运行态势持续向好。全行业完成运输总周转量151.8亿吨公里、旅客运输量7536.4万人次、货邮运输量86.5万吨,同比分别增长8%、3.3%、13.3%。(证券日报)

2小时前

量化指增多头保护策略悄然走红

今年以来,A股市场科技成长主线与小市值风格持续活跃,多个小微盘股代表性指数高弹性特征凸显。然而,高收益往往伴随着高波动,在市场情绪切换时的潜在回调风险不容忽视。在此背景下,近期记者调研了解到,以“量化增强收益保护”为主要出发点的量化指增多头保护策略,在私募业内悄然走红。该策略在股票现货端主要聚焦全市场量化选股或中小市值量化指增,在风险对冲端则主要采用股指期权等衍生品工具进行风险对冲和管理。目前,已有多家知名量化私募及FOF机构在该创新策略上展开新一轮竞逐。(中证报)

2小时前

李在明称无条件接受美国投资要求将使韩国陷入金融危机

韩国总统李在明近日接受采访时表示,如果政府在没有保障措施的情况下接受美国目前在陷入僵局的贸易谈判中的要求,韩国经济可能陷入与1997年一样的危机。首尔和华盛顿在7月份口头同意了一项贸易协议,其中美国同意降低对韩国商品的关税,以换取韩国3500亿美元的投资,以及其他措施。(新浪财经)

2小时前

外资机构频繁调研加速入市

国家外汇管理局9月19日公布的2025年8月份银行结售汇和银行代客涉外收付款数据显示,8月份跨境资金净流入32亿美元。据国家外汇管理局副局长、新闻发言人李斌介绍,8月份外资总体净买入境内股票和债券。国际金融协会(IIF)发布的报告显示,8月份外国投资者向新兴市场股票和债券投资组合投入近450亿美元,为近一年来的最高规模,其中流入中国市场投资组合的资金占据主要部分。同时,外资机构也在持续加快调研步伐,密切关注A股公司。进入9月份以来,高盛、瑞银等多家国际知名机构更是接连发表观点,看好中国资产。外资机构普遍认为,受人民币国际化提速、企业盈利回暖等多重利好共振,全球资金对A股市场的信心正在快速提升。(证券日报)

2小时前

本页详细列出关于隆顺榕的品牌信息,含品牌所属公司介绍,隆顺榕所处行业的品牌地位及优势。
咨询